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Summary. A simple pharmacokinetic model, incorporating linear plasma protein bind- 
ing, linear tissue binding, and first order elimination of free (unbound) drug, 
was studied. If Clp is the plasma clearance, Vf is the "true" volume of distribu- 
tion of free drug, B is the apparent elimination rate constant, ~ is the fraction 
of the drug which is free in plasma, f is the fraction of the drug which is free 
in the entire body, kf is the intrinsic elimination rate constant for free drug, 
and A~B is the initial amount of drug which is bound to tissues, then the model in- 
dicates that the following relationships hold: (I) Cl~ = Vf~ kf; (2) ~ = f kf; and 
Vdex t = (o/f) Vf. Only o, and not f, can be measured experimentally. Dividing Clp by 
provides an estimate of the intrinsic clearance of free drug, Vfkf. A plot of 
Vdext versus ~ has an intercept equal to Vf, and the ratio of the slope/intercept 
is" an estimate of A~/A~, where A~ is the initial amount of free drug (equalo to Vf 
times initial concentration of free drug in plasma). Thus, an estimate of A~B may 
be obtained. Dividing the intrinsic clearance by Vf provides an estimate of kf. 
• • O 
Thus, theoretlcally, est±mates of Vf, kf, ATB and f may be obtained. The variables 
are not separated when ~ is plotted versus ~, and curvature of such plots is expec- 
ted; no useful information is obtained from such plots. 
Key words: Plasma protein binding, tissue binding, volume of distribution of free 
drug, intrinsic rate constant for free drug, amount bound to tissues. 
There has been much discussion in the 
literature on the effects of plasma pro- 
tein binding on the distribution, elim- 
ination, and activity of drugs (Anton 
and Solomon, 1973; Benya and Wagner, 
1975; Coffey, 1972; Garrett, 1972; Keen, 
1972; KrHger-Thiemer, 1966 and 1968; Levy 
and Yacobi, 1974; Martin, 1965; Wagner, 
1971 and 1975) and these citations are 
not intended to be complete. The review 
of Keen (1971) not only discussed the 
mPartly supported by Public Health Service Grant 
5-P-II-GM 1559 and partly by Grant IROIAAOO683- 
possible effects of plasma protein bind- 
ing, but also discussed the possible ef- 
fects of tissue binding. He cited data 
showing that cardiac glycosides which are 
highly bound to plasma proteins are also 
highly bound to tissues. A similar sit- 
uation has been reported for diphenhy- 
dramine (Wagner, 1973 and Albert et el., 
1975) and for warfarin in the rat (Benya 
and Wagner, 1975; Yacobi and Levy, 1975). 
Several authors (Coffey, 1972; Garrett, 
1972; Keen, 1971; Kr~ger-Thiemer, 1966 
and 1968; Levy and Yacobi, 1974; Martin, 
1965; Yacobi and Levy, 1975) have devel- 
oped mathematical and pharmacokinetic 
models and equations which incorporate 
plasma protein binding. Others (DiSanto, 
OIAI from the National Institute on Alcohol Abuse 1971 and Wagner, 1971 and 1975) have de- 
and Alcoholism, Rockville, Maryland. veloped models to illustrate possible ef- 
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fects of tissue binding. Bischoff and 
Dedrick (1968) developed a flow rate- 
limited model, which incorporated both 
plasma protein binding and binding to 
several different types of tissues; they 
assumed that the relationship for bind- 
ing to plasma proteins could also be used 
for tissue binding; equations used were 
those of the Langmuir type. Hermann (1975) 
showed that the binding of ouabain and 
digitoxin by human erythrocytes obeyed 
the Langmuir equation. When the dissoci- 
ation constant is much greater than the 
drug concentration, the Langmuir equation 
collapses to a linear binding equation. 
In inter-individual comparisons of a 
group of one species of animal or man it 
would be advantageous if one could pre- 
dict, for example, the plasma clearance 
of a drug by measurement of the fraction 
of the drug which is free in plasma. The 
question arises as to which are the ap- 
propriate pharmacokinetic parameters to 
correlate with this fraction. The pur- 
pose of this report is to determine 
which relationship or relationships have 
a firm footing in pharmacokinetic theory, 
rather than the alternative approach of 
just making empirical correlations. The 
physical model approach also suggests 
when one might expect a trend line to be 
linear or curved; often, scatter in data, 
as a result of just biological variation 
and assay error, does not allow one to 
adequately determine when a trend line 
should be linear or curved. 
CTB- molar concentration of tissue bound 
drug at time t. 
D - the dose of drug administered by 
bolus intravenous injection. 
f - the fraction of the total amount of 
drug in the body which is free. 
(defined by equation 14). 
kf - the intrinsic elimination rate con- 
stant for free drug (dimension of 
I/time). 
Kp - the association constant for protein 
bound drug (Kp = kl/k2). 
K T - the association constant for tissue 
bound drug (KT = k3/k4) • 
m - the number of binding sites for drug 
on tissue protein. 
n - the number of binding sites on plas- 
ma protein. 
P - molar concentration of plasma pro- 
tein. 
- the fraction of drug which is free 
in plasma (defined by equation 19). 
t - time. 
t" - some specific time. 
t I - a lag time needed in real life to 
establish model conditions. 
T - molar concentration of tissue which 
binds the drug. 
Vdare a - a volume of distribution defined 
by equation 34. 
Vdext - a volume of distribution defined 
by equation 39. 
Vf - the "true" volume of distribution of 
free drug (dimension of liters). 
V T - the volume of tissue which binds 
drug (liters). 
THEORETICAL Assumptions 
Symbolism I. When the dose, D, is given by bolus 
intravenous injection, the drug instan- 
Af - amount (moles) of free drug at time t. taneously is partitioned into three por- 
tions, namely A~B , A~B , and A~. 
A~ - initial amount (moles) of free drug 
at time zero. 
ApB- amount (moles) of plasma protein 
bound drug at time t. 
A~B- initial amount (moles) of plasma 
protein bound drug at time zero. 
ATB- amount (moles) of tissue bound drug 
at time t. 
A~B- initial amount (moles) of tissue 
bound drug at time zero. 
8 - apparent elimination rate constant, 
such that -d in Cp/dt = 8 
Clp- plasma clearance ~defined by equa- 
tion 31). 
2. Binding to both plasma protein and 
tissue is linear and independent of drug 
concentration. 
3. The volume occupied by plasma pro- 
teins is ignored and hence ApB = VfCpB 
and Af = VfCf. 
4. The free drug is eliminated accord- 
ing to first order kinetics with rate 
constant equal to kf. 
5. Only free drug is available for 
elimination. 
Model 
Cf - molar concentration of free (unbound) The simple model includes only binding 
drug at time t. 
C~ - initial molar concentration of free 
(unbound) drug at time zero. 
Cp - molar total plasma concentration of 
drug (defined by equation 24) at 
time t. 
Cp o _ initial molar total plasma concen- 
tration of drug at time zero. 
CpB- molar concentration of plasma pro- 
tein bound drug at time t. 
of drug to one class of sites on one 
plasma protein, binding of drug to one 
class of sites on one type of tissue and 
one fluid volume. However, the approach 
taken with the simple model could be 
readily extended to more complicated mod- 
els as was done by DiSanto (1971) and 
Wagner (1971) with analogous nonlinear 
models. The conclusions reached with the 
simple model would be extrapolatable to 
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more complicated models of a similar 
type. The model is shown schematically 
in Scheme 1. 
I Volume = Vf Volume = V T 
Plasmakl.~__Plasma k3 
Protein---~Protein + Freel+ Tissue~_~___Tissue 
bound k 2 drug I k% bound 
drug I drug 
Scheme i. Modified "one compartment open model" 
incorporating linear tissue binding and linear 
plasma protein binding 
Equations 
For linear binding: 
CpB = n Kp P Cf 
ApB = Vf CpB = n Kp P Vf Cf 
= nKp P Af 
CTB = m K T T Cf 
ATB = V T CTB = m K T T V T Cf 
VT 





Af = Vf Cf Eq. (5) 
Mass balance gives: 
Af + ApB + ATB + kfl~'Af- dt = D 
Eq. (6) 
In equation 6, the term containing the 
integral represents the amount of drug 
eliminated between time zero and time t'. 
Differentiation of equation 6 with re- 
spect to time yields equation 7. 
dAf dApB dATB 
d--t-- + d~ + d~ + kf Af = O Eq. (7) 
Now, 
dAPB dApB dAf 
= - (n Kp P)-- 




dATB dATB dAf V T dAf 
= dAf dt - (m K T T ~ff) dt dt 
Eq. (9) 
Substituting from equations 8 and 9 
into equation 7 yields: 
dAf V T 
dt [I + n Kp + m K T T ~ff] + kf Af = O 
Eq. (I O) 
Rearrangement of equation 10 gives 
equation 11. 
dt VT Af 
+ n Kp P + m K T T 
Eq. (11) 
Substituting from equation 5 for Af 
and cancelling the Vf's on both sides 
yields equation 12 from equation 11. 
dCf I~ kf 
- Cf 
dt VT 
+ n Kp + m K T T ~f 
= B Cf Eq. (12) 
where B is the apparent elimination 





I + n Kp P + m K T T V-~ 
Eq. (13) 
If we define f as the fraction of the 




Af + ApB + ATB ApB ATB 
I + m-f + A-7- 
Eq. (14) 
From equation 2 we obtain: 
ApB 
Af - n Kp P 
From equation 4 we obtain: 
Eq. (I 5) 
ATB VT 
if - m K T T V--f Eq. (16) 
Substituting from equations 15 and 16 
into equation 14 gives equation 17. 
f = I Eq. (17) 
VT 
I + n Kp P + m K T T V--~ 
Substituting from equation 17 ~nto 
equation 13 gives equation 18. 
8 = f kf Eq. (18) 
Thus, according to this simple model, 
the apparent elimination rate constant, 
8, is a product of the intrinsic elimi- 
nation rate constant for free drug, kf, 
and the fraction of the total amount of 
drug in the body which is free, f. 
If we define a as the fraction of the 
drug which is free (unbound) in the vol- 
ume Vf (and plasma is assumed to be re- 





Cf Vf Cf 
Cf + CpB Vf Cf + Vf CpB 
Af I 
Af + ApB Ap B 
1 + -  
Af 
Eq. (I 9) 
ApB I 
- Eq. (20) 
Af 
Substituting from equation 20 into 
equation 14 and rearranging gives: 
f = ~ Eq. (21) 
I + (ATB)~ 
Af 
Substituting for f in equation 21 
gives equation 22. 
= ~ kf Eq. (22) 
B ( ATB ) 
+ Af 
Equation 22 indicates that for inter- 
individual comparisons of a drug in one 
species of animal or in man, a plot of 
the apparent elimination rate constant, 
~, versus the fraction of drug which is 
free in plasma, ~, will be gently curved 
over a small range of ~ values, even 
when the ratio ATB/A f is constant from 
individual to individual of the species. 
With the scatter expected in such a plot 
(because of expected non-constancy of 
the ATB/A f ratios) such curvature would 
be difficult to detect with real data. 
Integration of equation 12 yields 
equation 23. 
Cf = C~ e -Bt Eq. (23) 
The total plasma concentration, Cp, 
is given by equation 24, after substi- 
tuting from equation I for CpB. 
Cp = Cf + CpB = (I + n Kp P) Cf 
Eq. (24) 
Multiplying both sides of equation 23 
by (I + n Kp P) and utilizing equation 
24 gives equation 25. 
Cp = (I + n Kp P) C~ e -~t = C~ e -~t 
Eq. (25) 
where 
C~ = (I + n Kp P) C~ Eq. (26) 
Hence, the model predicts that the 
apparent elimination rate constant, ~, 
obtained from total plasma concentrations 
is the same as that obtained from free 
drug concentrations. 
The initial condition at time zero 
for the model is given by equation 27. 
÷A B=D Eq (27) 
In equation 27, A~, A~B , and A~B are 
the initial amounts existing as free 
drug, drug bound to tissues, and drug 
bound to plasma proteins, respectively, 
and D is the dose administered. In real 
life it would take some finite time, even 
when the values of k I and k 3 are large, 
to attain this "initial condition", but 
this lag time, tl, would most probably 
be small relative to the measured time 
courses of most drugs. The model assumes 
such partitioning, as indicated by equa- 
tion 27, has already occurred at time 
zero. Hence, in real life the only dif- 
ference would be that the D in equation 
27 would be replaced by A~, the apparent 
initial amount of drug in the body, such 
that A~ < D, and t would be replaced by 
(t - tl). 
An estimate would be 
A~ = D - Vfkf f~l Cfdt. 
o 
It may be readily seen that Cp is also 
given by equation 28. 
° I A~ + A~B D-- Eq. (28) 
Cp = A~ + A~B + A~B Vf 
Equations 14 and 19 also apply to the 
initial condition, as well as at any 
time t, hence substituting from those 
equations and cancelling the A~'s yields 
equation 29. 
f A~ + A~B 
- Eq. (29) 
A~ + A~B + A~B 
Substituting from equation 29 into 
equation 28 gives equation 30. 
The plasma clearance, Cip, is usually 
calculated as the ratio of %he dose to 
the total area under the total plasma 
concentration-time curve, as indicated 
by equation 31. 
D 
Cip - Eq. (31) 
f0 Cp dt 
Integration of equation 25 between 
the limits of t = 0 and t = ~, followed 
by substitution for C~ from equation 30, 
substitution for 8 from equation 18 and 
cancellation of the f's gives equation 
32. 
O 
I0 Cp dt Cp D 
8 Vf o kf Eq. (32) 
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Substituting for the integral in equa- ing and tissue binding of the drug. When 
tion 31 from equation 32 and cancellation plasma protein binding is very low (i.e. 
~÷ I and A~B/D+ 0), and tissue binding 
is large [i.e. A~B/D÷ I), then this 
of the D's yields equation 33. 
Clp = Vf ~ kf Eq. (33) 
Thus, according to the model, the cal- 
culated plasma clearance, CID, is the 
product of the intrinsic clearance of 
free drug, Vf kf, and the fraction of 
the drug which is free in plasma, ~. For 
inter-individual comparisons a plot of 
Clp versus ~ should yield a straight 
line, passing through the origin, with 
slope equal to Vf kf, providing that the 
intrinsic clearance of free drug is con- 
stant from one individual to the next. 
Alternatively, and preferred, the plasma 
clearance of each individual may be di- 
vided by the fraction of drug free in 
plasma for that individual to obatin in- 
dividual estimates of the intrinsic 
clearance, then these analyzed statisti- 
cally to obtain a measure of dispersion. 
Vdarea is usually calculated with 
equation 34. 
Vdarea D Clp : - Eq. (34) 
f0 Cp dt 
Substituting from equation 18 for B 
and from equation 33 for Clp into equa- 
tion 34, and cancellation of the kf's, 
gives equation 35. 
Vdare a : (f) Vf Eq. (35) 
Equation 35 indicates that in the ab- 
sence of both plasma protein binding and 
tissue binding (i.e. ~ = f = I), Vdare a 
= Vf. However, equation 35 also indicates 
that Vdare a is not a simple function of 
~, as is clarified below. 
Rearrangement of equation 27 gives 
equation 36. 
: D-A B- Eq (36) 
Substituting from equation 27 and 36 
into equation 14, and rearrangement 
yields equation 37. 
Ah 
f = I D D Eq. (37) 
Substituting for f from equation 37 
into equation 35 yields equation 38. 
Vdarea = A~ B A~ B Vf Eq. (38) 
I D D 
The portion of equation 38 marked off 
by square brackets can have a value rang- 
ing from much less than unity to much 
greater than unity, depending upon the 
relative degrees of plasma protein bind- 
bracketed portion will be much larger 
than unity, and Vdare a >> Vf. If a = 0.5 
and (A~B + A~B)/D = 0.5, then the brack- 
eted portion would be equal to unity and 
Vdarea = Vf. Even for a drug which is 
both very highly plasma protein bound 
and tissue bound, Vdare a could be equal 
to Vf; for example, if ~ = 0.02 and (A~B 
+ A~B)/D = 0.98, then the bracketed por- 
tion would be equal to unity. Usually, 
of course, the bracketed portion would 
not be equal to unity, hence either 
Vdare a > Vf or Vdarea < Vf. Thus, the 
calculated volume of distribution is not 
equal, usually, to the volume of distrib- 
ution of free drug. 
The extrapolated volume of distribu- 
tion, Vdext , is calculated with equation 
39. 
D 
Vdext - C~ Eq. (39) 
o 
Substituting for C D from equat±on 30 
into equation 39 yields equation 40. 
Vdext = (~) Vf Eq. (40) 
By comparing the right hand sides of 
equations 35 and 40 we see that for this 
model: 
Vdext = Vdare a Eq. (41) 
Equation 41 is the expected result 
for this modified "one compartment open 
model". If there was more than one fluid 
compartment and/or distribution to some 
tissues took an appreciable time, than a 
multicompartmental model would be re- 
quired, and, in such cases, Vdext > 
Vdarea- 
From equations 14 and 19 it may read- 
ily be shown that: 
VT (CTB) 
- I + (~ff) Cp Eq. (42) f 
Equation 42 indicates that ~ ~ f. 
Also, rearrangement of equation 34 gives 
equation 43. Hence, the model agrees 
with classical concepts. 
Cip = Vdare a B Eq. (43) 
Keen (1971) recommended that the vol- 
ume of distribution be calculated from 
free drug concentrations, rather than 
from total drug concentrations. If this 
is done, then the volume calculated, 
based on the simple model, is Vf/f. The 
same result would be obtained by divid- 
ing the volumes, Vdext and Vdarea, esti- 
mated from total drug concentrations, by 
~. It should be noted that such volumes 
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are still dependent upon relative degrees 
of plasma protein binding and tissue 
binding, as pointed out by Keen (1971). 
The product of the apparent elimination 
rate constant, 8, and such a volume 
(estimated from free drug concentrations) 
is, by use of equation 18, equal to the 
intrinsic clearance of free drug, as in- 
dicated by equation 44. 
Vf 
Intrinsic clearance = (~-) (f kf) 
= Vf kf 
Eq. (44) 
If there are multicompartmental phar- 
macokinetics, then the volume calculated 
from free drug concentrations should be 
the modified Vdarea, rather than Vdext , 
unless, as is sometimes the case, the 
two volumes are essentially identical. 
Estimation of Vf and ATB/A f - Substituting 
from equation 20 into equation 14 yields 
equation 45. The latter is also obtained 
by rearranging equation 21. 
I 




Substituting from equation 45 into 
equation 40 and simplifying gives equa- 
tio 46. 
( ATB ) 
Vdext : [I + o ] Vf Eq (46) 
Af 
Equation 46 indicates that a plot of 
Vdext versus ~ will be linear with inter- 
cept equal to Vf, and slope equal to 
(ATB/A f) Vf. Hence, ATB/A f is obtained 
with equation 47. 
ATB _ Slope _ (ATB/Af) Vf 
Af Intercept Vf 
Eq. (47) 
Estimation of kf and f - Since Vf is known 
(see above) and the intrinsic clearance, 
Vf kf, is known by dividing Clp by 
(equation 33), then an estimate of kf is 
obtained from equation 48. 
Intrinsic Clearance Vf kf 
kf = Vf - Vf 
Eq. (48) 
Now that kf and B are known, then "f" 
may be estimated by rearranging equation 
18 to give equation 49. 
f _ B kf Eq. (49) 
Estimation of A~B - If we write equation 
5 for the zero time condition, then equa- 
tion 50 is obtained. Also, since binding 
is linear, equation 51 holds. 
= vf (5o) 
ATB A~B 
- Eq. (51) 
Af A~ 
• . o o . 
Since the ratlo ATB/A f ±s known from 
equations 47 and 51, and A A~ is known 
from equation 50, then A~B is obtained 
with equation 52. 
o o 
A~B - ATB/Af 
Vf C~ Eq. (52) 
SIMULATIONS 
Simulation ~ ~ equation 22 - A plot of the 
apparent elimination rate constant, ~, 
versus the fraction free in plasma, o, 
does not separate the variables as may 
be seen from equation 22. Even in those 
cases where the ratio ATB/A f is constant, 
while o varies, plots of ~ versus o will 
be curved as may be seen in Figure I. 
The greater the value of the ratio ATB/Af, 
the greater the curvature. For low val- 
ues of ATB/Af, the plots are nearly lin- 
ear. In real life, one would expect 
ATB/A f to vary, and not be constant, from 
one individual to the next. This would 
cause scatter on the plots of B versus 
o. Evaluation of such "scattered data" 
by linear regression analysis, would 
lead to an apparent positive intercept 
on the ordinate. But, the intercept and 
slope values obtained from such plots 
would have no physical significance. 
Thus, correlations of B with o are notre- 
commended. This would also apply to any 
transformation, such as half-life. 
Simulation ~th equation 46 - Two sets of 
data were generated by letting ATB/A f 
equal 10 and 50, then varying o over the 
range 0.004 to 0.02. For a given value 
of o, the value of "f" was calculated 
with equation 45, then the corresponding 
value of o/f, equivalent to Vdext/Vf, was 
calculated using equation 40. Results 
are shown in Figure 2. Extrapolation of 
the linear plots to the ordinate yielded 
a value of unity, equal to Vf/Vf in this 
case. The slopes of the lines are the 
same as the assigned values of ATB/Af, 
namely 50 and 10. Suppose the value of 
Vf was 0.6 i/kg. Then, using the value 
of ATB/A f = 50, the slope of the Vdext 
versus ~ plot would be 30, and the inter- 
cept would be 0.6. Hence, the calculated 
value of ATB/A f would be slope/intercept 
= 30/0.6 = 50. If there was considerable 
scatter on a plot of Vdext versus ~, this 
would indicate variation in the ratio 
ATB/A f from one individual to the next. 
DISCUSSION 
The simple model employed incorporated 
linear tissue binding, linear plasma pro- 
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Fig. i. Results of simulations with equation 22 
(see text). Indicates curvature obtained when 
apparent elimination rate constant plotted versus 
fraction free in plasma. Numbers on curves refer 
to assigned values of the ratio ABT/A f 
2.0 
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Fig. 2. Results of simulations with equation 40 
(see text). Numbers on lines refer to assigned 
values of the ratio ATB/A f 
of free (unbound) drug, hence any con- 
clusions are limited to real systems with 
these properties. The most important 
equations derived are 18, 22, 33, 40, 
and 46 through 52, which require equa- 
tions 14, 19, 31, 34 and 39 for interpre- 
tation. 
With respect to inter-individual com- 
parisons, the model suggests the follow- 
ing: 
(I) Dividing the plasma clearance, Clp, 
(estimated from total plasma concentra- 
tions) by the fraction of drug free in 
plasma, a, will provide estimate of the 
intrinsic clearance of free drug, Vf kf. 
The values obtained from a panel of sub- 
jects or patients, or a group of animals, 
may then be treated statistically to ob- 
tain a mean and some measure of disper- 
sion, such as the coefficient of varia- 
tion. Alternatively, one could plot Clp 
versus g and the slope of the least 
squares linear regression line would be 
an estimate of Vf kf for the population. 
(2) A plot of the extrapolated volume 
of distribution, Vdext , versus fraction free 
in plasma, a, has an intercept equal to 
Vf and a slope equal to (ATB/Af) Vf, 
hence the ratio ATB/A f is obtained by 
dividing the slope by the intercept. Once 
V~ and ATB/A f are known, then kf, f, and 
A~B are readily obtained, providing there 
is not much variation in ATB/A{. 
(3) The apparent eliminatio~ rate con- 
stant, B, is equivalent to the product 
of'the intrinsic elimination rate con- 
stant for free drug, kf, and the frac- 
tion of the total drug in the body which 
is free, symbolized by f. It should be 
noted that B is not equal to ~ kf, unless 
there is absolutely no tissue binding. 
When B is plotted versus a, the variables 
are not separated, and the plot will have 
a gentle curvature. If, also, ATB/A f 
varies appreciably from one individual 
to the next, then there will be consider- 
able scatter on the 6 versus ~ plots. 
These types of plots are not recommended. 
Since the binding of drugs to plasma 
proteins is extremely rapid (Keen, 1971) 
and the binding of some drugs to tissues 
is also extremely rapid (see Wagner, 1973 
for diphenhydramine in the rat; and Benya 
and Wagner, 1975 for warfarin in the rat), 
one might expect the model to hold for 
low doses in some cases. It should be 
noted that if one derives equations for 
a similar model, but with several dif- 
ferent types of tissues, the same general 
form for equation 17 is obtained, except 
that there are additional terms in the 
denominator for each type of tissue (see 
Wagner, 1971). 
The equations derived in this article 
and the conclusions reached differ ap- 
preciably from some of those of Keen 
(1971), Coffey (1972), Krfiger-Thiemer 
(1966 and 1968), Levy and Yacobi (1974) 
and Yacobi and Levy (1975). The reason 
for the differences is the inclusion of 
both tissue binding and plasma protein 
binding in the model and derivations in 
the present article, whereas previous 
authors cited were principally concerned 
only with plasma protein binding. It is 
hoped that this article will aid in ob- 
taining additional pharmacokinetic in- 
formation when a drug is administered by 
bolus intravenous injection to either a 
panel of subjects or patients or to a 
group of animals of one species. Also, 
it discloses some possible pitfalls in 
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